Utility of co-transplanting mesenchymal stem cells in islet transplantation

Naoaki Sakata, Gumpei Yoshimatsu, Shinichi Egawa, Michiaki Unno, Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8574, Japan.
World Journal of Gastroenterology (Impact Factor: 2.37). 12/2011; 17(47):5150-5. DOI: 10.3748/wjg.v17.i47.5150
Source: PubMed

ABSTRACT Islet transplantation is characterized by the transplantation of isolated islets from donor pancreata into a diabetic recipient. Although it is a viable choice in the treatment of insulin dependent diabetes mellitus, most patients (approximately 90%) require insulin five years after transplantation. Recently, the co-transplantation of mesenchymal stem cells (MSCs) and islets in animal studies has revealed the effectiveness of MSCs co-transplantation for improving islet function. The mechanisms underlying the beneficial impact of MSCs include immunomodulation and the promotion of angiogenesis. In this review, we discuss MSCs and how they support improved graft survival and function.

Download full-text


Available from: Naoaki Sakata, Sep 25, 2015
17 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cell-surface sensors are powerful tools to elucidate cell functions including cell signaling, metabolism, and cell-to-cell communication. These sensors not only facilitate our understanding in basic biology but also advance the development of effective therapeutics and diagnostics. While genetically encoded fluorescent protein/peptide sensors have been most popular, emerging cell surface sensor systems including polymer-, nanoparticle-, and nucleic acid aptamer-based sensors have largely expanded our toolkits to interrogate complex cellular signaling and micro- or nano-environments. In particular, cell-surface sensors that interrogate in vivo cellular microenvironments represent an emerging trend in the development of next generation tools which biologists may routinely apply to elucidate cell biology in vivo and to develop new therapeutics and diagnostics. This review focuses on the most recent development in areas of cell-surface sensors. We will first discuss some recently reported genetically encoded sensors that were used for monitoring cellular metabolites, proteins, and neurotransmitters. We will then focus on the emerging cell surface sensor systems with emphasis on the use of DNA aptamer sensors for probing cell signaling and cell-to-cell communication. WIREs Nanomed Nanobiotechnol 2012, 4:547–561. doi: 10.1002/wnan.1179 For further resources related to this article, please visit the WIREs website.
    Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology 07/2012; 4(5):547-61. DOI:10.1002/wnan.1179 · 4.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mesenchymal stem cells (MSCs) are self-renewing cells with multipotent differentiation characteristics and capability for the regulation of immune response. Accordingly, in the context of diabetes research, the ability of MSC to generate insulin-producing cells and to enhance islet engraftment and survival makes them attractive as new therapeutic agents for treatment of diabetes and related complications. In this chapter we emphasized the role of MSCs in the repair of β cell mass and function and we described the capacity of MSCs to modulate the autoimmune response during the pathogenesis of diabetes mellitus. In addition, we also presented here the mechanisms, promises and potential obstacles for MSC therapy of diabetic complications: cardiomyopathy, critical limb ischemia, nephropathy, polyneuropathy, retinopathy and diabetic wounds.
    Essentials of Mesenchymal Stem Cell Biology and Its Clinical Translation, 01/2013: pages 207-227; , ISBN: 978-94-007-6715-7
  • [Show abstract] [Hide abstract]
    ABSTRACT: Co-transplantation of islets with mesenchymal stem cells (MSCs) has been shown to improve graft outcome in mice, which has been partially attributed to the effects of MSCs on revascularization and preservation of islet morphology. Microencapsulation of islets provides an isolated-graft model of islet transplantation that is non-vascularized and prevents islet aggregation to preserve islet morphology. The aim of this study was to investigate whether MSCs could improve graft outcome in a microencapsulated/isolated-graft model of islet transplantation. Mouse islets and kidney MSCs were co-encapsulated in alginate, and their function was assessed in vitro. A minimal mass of 350 syngeneic islets encapsulated alone or co-encapsulated with MSCs (islet+MSC) were transplanted intraperitoneally into diabetic mice, and blood glucose concentrations were monitored. Capsules were recovered 6 weeks after transplantation, and islet function was assessed. Islets co-encapsulated with MSCs in vitro had increased glucose-stimulated insulin secretion and content. The average blood glucose concentration of transplanted mice was significantly lower by 3 weeks in the islet+MSC group. By week 6, 71% of the co-encapsulated group were cured compared with 16% of the islet-alone group. Capsules recovered at 6 weeks had greater glucose-stimulated insulin secretion and insulin content in the islet+MSC group. MSCs improved the efficacy of microencapsulated islet transplantation. Using an isolated-graft model, we were able to eliminate the impact of MSC-mediated enhancement of revascularization and preservation of islet morphology and demonstrate that the improvement in insulin secretion and content is sustained in vivo and can significantly improve graft outcome.
    Cytotherapy 02/2013; 15(2):192-200. DOI:10.1016/j.jcyt.2012.10.018 · 3.29 Impact Factor
Show more